diarrhea while on glp 1 tirzepatide (Mounjaro) affects approximately 23–31% of patients and is typically mild to moderate, transient, and most common during dose escalation. , It rarely requires discontinuation Effects of GLP-1 receptor agonist
Pay in 4 interest-free payments of $6.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

























